In the STEP and SURMOUNT trial programs, participants treated with semaglutide and tirzepatide respectively achieved average weight reductions of 15 to 22% of total body weight, losses that had previously been achievable only through bariatric surgery [8,9]
A newer study, published by multiple research sites that analyzed six population databases from Canada, Denmark, Norway, South Korea, Sweden, and Taiwan found no increased thyroid cancer risk between GLP-1RA users and DPP-4i recipients [4]
High Blood Pressure Weight-loss medications can cause an abnormal increase in blood pressure, as these drugs may interfere with proper blood circulation, leading to insufficient blood flow to vital organs
Zofran has a multitude of uses for palliative care, chief among them the prevention of nausea and vomiting in patients that have undergone chemotherapy or radiation treatment for cancer